Compare ACEL & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACEL | SLS |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 924.5M |
| IPO Year | 2017 | 2007 |
| Metric | ACEL | SLS |
|---|---|---|
| Price | $12.01 | $9.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $14.67 | $10.00 |
| AVG Volume (30 Days) | 241.1K | ★ 7.5M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.34 | ★ 50.00 |
| EPS | ★ 0.17 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.07 | N/A |
| Revenue Next Year | $2.81 | $110.98 |
| P/E Ratio | $70.71 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.55 | $1.39 |
| 52 Week High | $14.00 | $15.88 |
| Indicator | ACEL | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 39.58 | 41.57 |
| Support Level | $11.71 | $3.91 |
| Resistance Level | $13.29 | $15.88 |
| Average True Range (ATR) | 0.31 | 1.20 |
| MACD | -0.03 | -0.49 |
| Stochastic Oscillator | 11.81 | 16.96 |
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.